background
experiment
inocul
import
tool
common
cold
asthma
research
produc
rhinoviru
rv
inocula
nasal
secret
requir
prolong
observ
viru
donor
exclud
extran
pathogen
produc
inoculum
use
revers
genet
determin
dose
necessari
caus
moder
cold
seroneg
volunt
method
consensu
sequenc
previou
inoculum
clone
inoculum
viru
produc
use
revers
genet
techniqu
safeti
test
volunt
inocul
either
n
placebo
n
jackson
cold
score
record
nasal
secret
test
shed
ribonucl
acid
result
revers
genet
process
produc
infecti
viru
neutral
specif
antisera
mutat
rate
similar
convent
viru
growth
techniqu
median
tissu
cultur
infecti
dose
tcid
dose
produc
moder
cold
individu
effect
similar
previous
test
convent
inoculum
conclus
revers
genet
techniqu
produc
inoculum
caus
clinic
cold
seroneg
volunt
also
serv
stabl
sourc
viru
laboratori
use
recombin
product
procedur
elimin
need
deriv
seed
viru
nasal
secret
thu
preclud
introduct
extran
pathogen
rout
rhinovirus
rv
frequent
caus
common
cold
also
caus
lower
respiratori
ill
suscept
popul
includ
young
children
elderli
immunocompromis
individu
peopl
chronic
respiratori
condit
asthma
chronic
obstruct
lung
diseas
cystic
fibrosi
although
morbid
associ
respiratori
ill
consider
specif
treatment
lack
rv
experiment
inocul
model
use
investig
mechan
rv
pathogenesi
transmiss
test
efficaci
treatment
common
cold
understand
rv
infect
contribut
acut
exacerb
chronic
airway
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
recent
advanc
safeti
test
technolog
led
introduct
new
standard
current
good
manufactur
procedur
gmp
product
viral
inocula
tradit
method
produc
viru
inoculum
use
experiment
infect
isol
seed
viru
nasal
secret
donor
infect
via
natur
exposur
approach
labor
intens
donor
need
check
infecti
agent
observ
year
ensur
coinfect
report
describ
develop
revers
genet
rg
approach
produc
inoculum
major
group
clinic
isol
approach
advantag
compar
tradit
procedur
first
sever
new
respiratori
virus
eg
middl
eastern
respiratori
syndrom
coronaviru
wu
ki
polyomavirus
discov
past
decad
addit
infecti
agent
like
discov
futur
therefor
difficult
ensur
nasal
secret
chosen
isol
seed
viru
contain
pathogen
problem
minim
use
clone
viral
genom
produc
inoculum
viru
vitro
second
potenti
advantag
abil
produc
multipl
inocula
clone
sequenc
ribonucl
acid
rna
virus
rv
high
mutat
rate
genom
replic
rna
polymeras
errorcorrect
function
complementari
deoxyribonucl
acid
cdna
clone
amplifi
highli
accur
escherichia
coli
dna
polymeras
provid
stabl
sourc
viru
sequenc
product
futur
inocula
paper
describ
develop
inoculum
firstinhuman
phase
studi
assess
safeti
human
identifi
dose
need
produc
moderatetosever
cold
human
volunt
passag
human
lung
fibroblast
viral
cultur
univers
wisconsinmadison
thaw
novemb
use
produc
master
cell
bank
waisman
clinic
biomanufactur
facil
madison
wi
gmp
condit
extens
test
ident
qualiti
safeti
reveal
evid
microbi
viral
contamin
supplement
data
supplement
tabl
safeti
test
inoculum
direct
us
food
drug
administr
regulatori
agenc
neg
contamin
adventiti
agent
supplement
tabl
studi
approv
univers
wisconsinmadison
health
scienc
institut
review
board
protocol
studi
particip
household
contact
provid
written
inform
consent
regulatori
approv
list
supplement
tabl
anim
experi
conduct
approv
iit
research
institut
chicago
il
iacuc
protocol
data
support
public
avail
immport
immportorg
studi
access
inocul
studi
singleblind
adapt
dose
design
dose
escal
deescal
maximum
dose
group
adult
subject
inclus
criteria
includ
otherwis
healthi
adult
year
age
neutral
antibodi
inoculum
viru
exclus
criteria
includ
chronic
respiratori
diseas
smoke
subject
household
contact
deem
atrisk
eg
pregnanc
elderli
young
children
detail
inclus
exclus
criteria
list
supplement
tabl
subject
inocul
day
either
placebo
phosphatebuff
salin
human
serum
albumin
median
tissu
cultur
infecti
dose
tcid
supplement
tabl
inoculum
administ
aerosol
mad
nasal
intranas
mucos
atom
devic
teleflex
morrisvil
nc
administ
via
nostril
initi
dose
tcid
subject
inocul
given
dose
level
dose
next
group
subject
determin
base
clinic
symptom
previou
subject
dose
receiv
previou
subject
detail
supplement
figur
supplement
tabl
studi
design
maximum
subject
would
receiv
dose
level
placebo
tcid
symptom
score
modifi
jackson
cold
symptom
score
supplement
figur
assess
twice
daili
subject
begin
day
inocul
continu
least
day
symptom
resolv
final
visit
daili
symptom
score
repres
sum
highest
score
pm
score
obtain
symptom
peak
symptom
score
subject
repres
highest
daili
symptom
score
evalu
period
sever
induc
cold
studi
particip
defin
peak
symptom
score
categor
either
mild
score
moder
score
sever
score
mean
cold
symptom
score
dose
group
averag
peak
symptom
score
nasal
lavag
perform
cell
count
diagnost
virolog
detail
onlin
supplement
preinocul
nasal
lavag
assay
multiplex
polymeras
chain
reaction
pcr
rvp
luminex
austin
tx
detect
viru
present
time
inocul
nasal
lavag
fluid
collect
inocul
test
rvspecif
quantit
revers
transcript
rt
pcr
partial
genom
sequenc
confirm
infect
determin
viral
load
viral
shed
determin
quantit
pcr
qpcr
report
log
rna
copiesml
serum
obtain
day
inocul
also
test
rv
qpcr
assess
viremia
primari
endpoint
studi
identifi
dose
caus
cold
least
moder
intens
peak
symptom
score
first
week
longer
discret
princip
investig
case
delay
peak
symptom
inocul
safeti
determin
advers
event
report
secondari
endpoint
mean
cold
symptom
score
per
dose
infect
rate
per
dose
percentag
individu
dose
group
detect
rna
nasal
secret
mean
cold
symptom
score
dose
versu
placebo
safeti
laboratori
test
includ
complet
blood
count
differenti
platelet
blood
urea
nitrogen
creatinin
aspart
aminotransferas
alanin
aminotransferas
immunoglobulin
ig
igg
serum
ig
drawn
screen
determin
elig
day
inocul
monitor
inoculuminduc
laboratori
chang
close
contact
research
subject
see
onlin
supplement
detail
invit
join
surveil
studi
obtain
inform
frequenc
natur
transmiss
cold
clinic
characterist
consent
contact
collect
coldlik
symptom
score
use
modifi
jackson
criteria
begin
day
inocul
visit
consecut
day
cold
symptom
report
contact
ask
collect
nasal
secret
use
noseblow
techniqu
viral
diagnost
sampl
size
estim
examin
oper
characterist
propos
dose
rang
studi
design
varieti
scenario
expect
find
base
result
previou
doserang
studi
lot
grown
standard
techniqu
test
infect
dose
tcid
ml
associ
median
mean
peak
symptom
score
moder
rang
least
subject
moderatetosever
cold
tabl
expect
sampl
size
optim
dose
closest
avail
dose
rang
subject
probabl
cohort
receiv
closest
avail
dose
target
less
scenario
relationship
dose
logtransform
rate
cold
least
moder
intens
maxim
weekli
symptom
score
modifi
jackson
criteria
inocul
assess
use
logist
regress
model
logist
regress
equat
solv
optim
dose
eg
dose
estim
rate
moderatetosever
cold
recombin
inoculum
produc
use
step
viral
clone
sourc
recombin
genet
sequenc
previou
lot
human
inoculum
cryopreserv
use
extens
viru
inocul
sourc
viru
product
viral
inocula
viru
grown
use
tradit
cultur
techniqu
figur
use
addit
experiment
inocul
studi
viral
rna
extract
overlap
cdna
segment
viral
genom
amplifi
rtpcr
clone
sequenc
clone
cdna
segment
consensu
sequenc
select
assembl
stepwis
fashion
cdna
clone
fulllength
viral
genom
supplement
figur
result
plasmid
sequenc
entir
unexpect
sequenc
found
genbank
access
number
produc
infecti
viru
rna
synthes
transfect
cell
infecti
viru
releas
freezethaw
debri
remov
filtrat
centrifug
safeti
test
inoculum
reveal
evid
toxin
adventiti
agent
supplement
tabl
error
rate
rv
polymeras
high
rv
type
exist
quasispeci
consensu
sequenc
rapidli
adapt
differ
condit
vitro
vivo
produc
round
replic
compar
use
passag
use
tradit
techniqu
hypothes
rg
procedur
would
introduc
fewer
mutat
refer
sequenc
test
hypothesi
compar
fulllength
sequenc
inocula
produc
use
convent
techniqu
mutat
mutat
mutat
figur
volunt
screen
studi
gave
inform
consent
test
neutral
antibodi
detect
antibodi
figur
studi
subject
inocul
mean
age
year
includ
men
women
tabl
individu
met
studi
criteria
provid
inform
consent
similar
screen
popul
tabl
total
subject
inocul
tcid
tcid
dose
addit
subject
group
plu
replac
due
detect
communityacquir
viru
inocul
tcid
subject
placebo
inocul
although
none
subject
report
cold
time
inocul
subject
subject
tcid
dose
group
respect
found
communityacquir
rv
genotyp
nasal
secret
baselin
andor
first
week
inocul
subject
exclud
analysi
effect
cold
symptom
viral
rna
shed
due
low
remain
number
n
subject
inocul
tcid
ml
dose
level
includ
subsequ
analys
two
subject
inocul
placebo
communityacquir
rv
detect
nasal
secret
day
mockinocul
inocul
induc
clinic
cold
individu
percentag
cold
least
moder
sever
dose
relat
tabl
placebo
group
tcid
group
tcid
group
thu
tcid
dose
met
dose
select
criteria
studi
subject
inocul
dose
group
infect
indic
detect
rna
sampl
nasal
secret
obtain
within
day
inocul
figur
rhinoviru
inocul
significantli
increas
cold
symptom
score
day
inocul
subject
shed
nasal
secret
least
day
inocul
serum
sampl
obtain
day
postinocul
pi
neg
viremia
data
shown
neutral
antibodi
respons
day
pi
similar
tcid
tcid
dose
group
subject
group
posit
miss
valu
tcid
group
sever
doserel
effect
note
compar
cours
cold
inocul
vs
tcid
figur
tcid
group
report
slightli
higher
symptom
score
baselin
median
vs
p
inocul
tcid
group
increas
symptom
score
day
pi
greater
viral
rna
shed
day
pi
inocul
tcid
increas
leukocyt
count
nasal
wash
fluid
peak
symptom
score
group
also
dose
relat
mean
valu
placebo
tcid
dose
group
tabl
time
peak
symptom
score
similar
occur
day
inocul
tcid
day
inocul
tcid
median
p
nonsignific
total
household
close
contact
studi
subject
consent
surveil
natur
transmiss
three
contact
report
cold
symptom
monitor
period
one
contact
test
posit
commun
viru
one
test
posit
inoculum
viru
third
test
neg
rv
common
respiratori
virus
contact
test
posit
inoculum
viru
mild
respiratori
symptom
day
subject
inocul
resolv
day
cold
symptom
restart
day
index
inocul
peak
score
next
day
report
symptom
headach
congest
consist
sinus
howev
symptom
complet
resolv
week
later
day
index
inocul
nasal
secret
household
contact
test
posit
inoculum
strain
day
inocul
index
case
studi
subject
inocul
advers
event
classifi
relat
possibl
relat
inocul
cold
sore
day
pi
episod
sinus
includ
household
contact
mention
anterior
cervic
lymphadenopathi
acut
ill
transient
judg
mild
sever
perform
doserang
studi
inoculum
produc
use
convent
procedur
figur
procedur
use
studi
similar
except
differ
devic
devilbiss
atom
vs
mucos
atom
devic
teleflex
morrisvil
nc
current
studi
use
atom
administ
viral
suspens
case
dose
need
produc
cold
least
moder
sever
particip
tcid
mean
peak
symptom
score
similar
tabl
studi
establish
rv
use
human
inocul
studi
produc
use
rg
technolog
advantag
approach
includ
increas
assur
viral
inoculum
contamin
extran
pathogen
seed
viru
deriv
clone
rv
sequenc
pathogenfre
cultur
cell
instead
undefin
nasal
secret
doserang
inocul
studi
dose
tcid
produc
cold
inocul
notabl
viral
replic
cold
symptom
quit
similar
induc
previou
inoculum
viru
produc
use
tradit
techniqu
anoth
advantag
approach
clone
viru
provid
genet
stabl
sourc
viru
e
coli
polymeras
use
replic
plasmid
error
rate
compar
picornaviru
polymeras
thu
sequenc
plasmid
quit
stabl
enabl
reliabl
sourc
viru
product
import
featur
picornavirus
serial
passag
tissu
cultur
adapt
quickli
cultur
cell
chang
function
characterist
demonstr
suspens
acquir
numer
fewer
mutat
compar
convent
grown
virus
like
due
less
time
tissu
cultur
rg
enabl
viru
produc
quickli
easili
larg
quantiti
thu
possibl
use
virus
virtual
ident
inocul
studi
vitro
studi
contrast
mani
virus
use
laboratori
studi
come
american
type
cultur
collect
isol
adapt
tissu
cultur
cell
line
hela
cell
notabl
sequenc
differ
previous
sequenc
helaadapt
laboratori
strain
approxim
base
data
shown
repres
differ
approxim
similar
genet
discord
mous
rat
find
underscor
util
stabl
sequenc
sourc
use
make
viru
suspens
high
degre
sequenc
ident
use
inocul
studi
vitro
studi
studi
design
identifi
dose
would
caus
cold
moder
sever
least
studi
subject
symptom
viral
rna
shed
dose
relat
notabl
volunt
inocul
develop
infect
communityacquir
virus
subject
communityacquir
virus
present
yet
symptomat
day
inocul
either
coinfect
sequenti
infect
establish
demonstr
import
screen
virus
inocul
studi
determin
type
virus
detect
one
challeng
conduct
studi
prolong
regulatori
pathway
firstinhuman
recombin
rv
inoculum
supplement
tabl
delay
due
regulatori
chang
prompt
influenza
epidem
rais
concern
introduc
viru
wild
synthes
laboratori
albeit
wildtyp
sequenc
addit
detect
porcin
circoviru
liveattenu
rotaviru
vaccin
led
addit
requir
test
viral
inoculum
bovin
porcin
virus
could
theoret
introduc
anim
product
eg
serum
use
manufactur
rg
procedur
rv
establish
product
addit
viral
vaccin
inocula
use
recombin
techniqu
straightforward
viru
clone
product
process
one
signific
delay
tradit
product
process
inocula
grown
nasal
secret
viru
donor
must
undergo
thorough
test
infecti
agent
followup
recommend
use
clone
viru
instead
nasal
secret
sourc
seed
viru
obviat
delay
strength
studi
includ
use
novel
viral
inoculum
use
viral
diagnost
identifi
commun
virus
studi
subject
molecular
character
virus
detect
also
document
first
time
low
risk
transmiss
inoculum
viru
household
contact
anoth
potenti
advantag
rg
approach
could
use
futur
studi
effect
mutat
specif
viral
sequenc
limit
includ
inclus
healthi
adult
studi
subject
possibl
individu
chronic
respiratori
diseas
eg
asthma
copd
could
develop
upper
even
lower
respiratori
ill
lower
dose
viru
conclus
develop
first
recombin
rv
inoculum
use
rg
techniqu
demonstr
induc
cold
similar
intens
caus
tradit
inocula
use
clone
viru
elimin
one
potenti
sourc
contamin
provid
genet
stabl
sourc
simplifi
manufactur
pathway
product
rv
human
inocul
studi
furthermor
sever
rv
clinic
strain
clone
techniqu
could
use
produc
addit
inocula
includ
rvc
investig
rv
pathogenesi
efficaci
antivir
drug
vaccin
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
